Core Viewpoint - GeneDx stock (NASDAQ: WGS) experienced a 14% decline following the release of preliminary full-year 2025 results that met expectations, alongside a disappointing 2026 guidance that raised concerns among investors [1] Group 1: Financial Performance - The company reported preliminary full-year 2025 results that aligned with market expectations [1] - The stock's significant drop indicates investor reaction to future guidance rather than current performance [1] Group 2: Future Guidance - GeneDx provided guidance for 2026 that was perceived negatively by investors, contributing to the stock's decline [1]